|
Titus
F, Davalos A, Alom J, et al. 5-hydroxytryptophan versus methysergide
in the prophylaxis of migraine: randomized clinical trial. Eur
Neurol. 1986;25:327–329.
Bono
G, Criscuoli M, Martignoni E, et al. Serotonin precursors in
migraine prophylaxis. Adv Neurol. 1982;33:357–363.
Santucci
M, Cortelli P, Rossi PG, et al. L-5-hydroxytryptophan versus placebo
in childhood migraine prophylaxis: a double-blind crossover study.
Cephalalgia. 1986;6:155–157.
De
Giorgis G, Miletto R, Iannuccelli M, et al. Headache in association
with sleep disorders in children: a psychodiagnostic evaluation and
controlled clinical study-L-5-HTP versus placebo. Drugs Exp Clin
Res. 1987;13:425–433.
Longo
G, Rudoi I, Iannuccelli M, et al. Treatment of essential headache in
developmental age with L-5-HTP (cross over double-blind study versus
placebo) [in Italian; English abstract]. Pediatr Med Chir.
1984;6:241–246.
De
Benedittis G, Massei R. Serotonin precursors in chronic primary
headache. A double-blind cross-over study with L-5-Hydroxytryptophan
vs. placebo. J Neurosurg Sci. 1985;29:239–248.
Maissen
CP, Ludin HP. Comparison of the effect of 5-hydroxytryptophan and
propranolol in the interval treatment of migraine . Schweizerische
Medizinische Wochenschrift /Journal Suisse de Medecine
1991;121:1585–90 [in German].
Mathew
NT. 5-hydroxytryptophan in the prophylaxis of migraine. Headache
1978;18:111–3.
De
Giorgis G, Miletto R, Iannuccelli M, et al. Headache in association
with sleep disorders in children: A psychodiagnostic evaluation and
controlled clinical study ñ L-5-HTP versus placebo. Drugs
Exptl Clin Res
1987;13:425–33.
L-5-Hydroxytryptophan
versus placebo in childhood migraine prophylaxis: a double-blind
crossover study
Margherita
Santucci11Childhood
Neuropsychiatry Chair, University of Bologna, Bologna, Italy; ,
Pietro Cortelli22Institute
of Clinical Neurology, University of Bologna, Bologna, Italy,
Paola Giovanardi Rossi11Childhood
Neuropsychiatry Chair, University of Bologna, Bologna, Italy; ,
Agostino Baruzzi22Institute
of Clinical Neurology, University of Bologna, Bologna, Italy,
Tommaso Sacquegna22Institute
of Clinical Neurology, University of Bologna, Bologna, Italy
Childhood Neuropsychiatry
Chair, University of Bologna, Bologna, Italy; 2Institute
of Clinical Neurology, University of Bologna, Bologna, Italy
Correspondence to Tommaso Sacquegna, Centro Cefalee, Clinica
Neurologica, Via U. Foscolo 7, 40123 Bologna, Italy;
L-5HTP was tested versus placebo in a double-blind crossover study of
27 migraine children aged 6–12 years, who recorded their headaches
in a headache diary for 1 month. Twenty-one patients subsequently
started the trial. The mean daily dose of L-5HTP was 5 mg/kg body
weight, and each treatment period with either L-5HTP or placebo
lasted 12 weeks. In group A (L-5HTP-placebo; 10 patients) and group B
(placebo-L-5HTP; 11 patients) both L-5HTP and placebo led to a
significant reduction of the migraine index and frequency of migraine
attacks during the 3rd month of each treatment period. However, we
found a treatment x period interaction because the efficacy
determinants decreased significantly during the first and the second
treatment periods in both groups irrespective of the sequence of
treatments. No differences were found between L-5HTP (first period of
group A) and placebo (first period of group B).
|
